NeoGenomics, Inc.
—- Market cap
- —
- Debt
- +$341.86M
- Cash
- −$159.62M
Complete market value, debt and cash evidence is required for enterprise value.
Compare price, profitability, solvency, and SEC-reported financials side by side—before deciding which assumptions deserve a closer look.
Decision snapshot: NEO stock price vs ANSS: inconclusive Relative valuation is incomplete for this pair. Review the available filing metrics before drawing a conclusion.
Quick read
Each company valued on the other's multiple, then compared with the market price.
Implied fair value · at ANSS's multiple
Needs ANSS P/S.
Implied fair value · at NEO's multiple
Needs NEO P/S.
Metric by metric
Where each company leads, and how wide the gap is.
Price unavailable
Growth lag
Pricing power
Operating leverage
Lower is better
Not comparable
Lower leverage
Statements
Core statements aligned to each company's latest fiscal year.
SEC periods: NEO FY 2025 (ended Dec 31, 2025) · ANSS FY 2024 (ended Dec 31, 2024). Fiscal years are not aligned.
Trendline
Ten fiscal years of revenue, earnings, and margins before underwriting a re-rating.
Price framework
Market cap plus debt, less cash.
Complete market value, debt and cash evidence is required for enterprise value.
Complete market value, debt and cash evidence is required for enterprise value.
Price framework
The same filing-backed model used on each company's valuation page, with company-specific inputs and calculated scenarios.
NeoGenomics, Inc. · implied price per share
Latest annual free cash flow must be positive to qualify the filing-backed baseline.
ANSYS, Inc. · implied price per share
Debt and bridge-cash inputs are required to translate enterprise value into equity value.
Balance sheet health
Financial health checks to separate durable balance sheets from potential value traps.
Financial strength on a 0–9 scale.
Bankruptcy-risk signal from balance sheet and earnings power.
Not enough data to score either balance sheet.
Debt / equity
Total debt against shareholders' equity
0.41x
0.12x
Net debt / EBITDA
Leverage against operating earnings
-4.48x
0.84x
Cash and equivalents
Liquid reserves on the balance sheet
$159.62M
$50.77M
Total debt
Interest-bearing obligations outstanding
$341.86M
$755.00M
Comparable set
Where the pair sits against the wider comparable set.
Keep comparing
Open adjacent comparisons from the same industry to pressure-test the read across multiple pairs.
LABCORP HOLDINGS INC.
NEO vs LH
QUEST DIAGNOSTICS INC
NEO vs DGX
OPKO HEALTH, INC.
NEO vs OPK
Guardant Health, Inc.
NEO vs GH
Natera, Inc.
NEO vs NTRA
EXACT SCIENCES CORP
NEO vs EXAS
Autodesk, Inc.
NEO vs ADSK
TRIMBLE INC.
NEO vs TRMB
CADENCE DESIGN SYSTEMS INC
NEO vs CDNS
Altair Engineering Inc.
NEO vs ALTR
PTC INC.
NEO vs PTC
ADOBE INC.
NEO vs ADBE
LLM-powered synthesis
An explanation of the financial evidence. Check its snapshot date against the figures above.
The deterministic comparison remains available. Sign in when you want an on-demand narrative synthesis of the same data.